Managed care allergy survey
This article was originally published in The Tan Sheet
Executive Summary
Forty-eight percent of managed care organizations "promote or have educational programs to utilize [Schering-Plough's] Claritin (OTC) over Clarinex (Rx)," according to survey conducted by The New England Consulting Group on "the draconian steps being taken to reduce pharmaceutical costs." Data compiled from responses of 41 major MCOs also indicates 78% of health plans have "promoted or educated...members on OTC allergy alternatives to Clarinex, [Aventis'] Allegra and [Pfizer's] Zyrtec"...
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.